John Tremblay
Cardiovascular Disease · Albany, NYNPI 1417584137
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.9% of the total across 98 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AOP Health US, LLC at 33.6% of the total.
Across 98 payments — averaging $59.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AOP Health US, LLC$2K
- Abiomed$980
- Edwards Lifesciences$623
- Medtronic$329
- Johnson & Johnson$218
- Novartis$204
- plus $2K from 21 others
What the payments were for
- Food & beverage$5,49494%
- Education$3556%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AOP Health US, LLC | 2 | $1,967 |
| Abiomed | 16 | $980 |
| Edwards Lifesciences | 21 | $623 |
| Medtronic | 6 | $329 |
| Johnson & Johnson(2 entities) | 3 | $218 |
| Novartis | 8 | $204 |
| Abbott | 4 | $202 |
| AstraZeneca | 3 | $169 |
| E.r. Squibb & Sons, L.L.C. | 3 | $158 |
| Cvrx, Inc. | 6 | $135 |
| AbbVie | 1 | $125 |
| Boehringer Ingelheim | 1 | $125 |
| Shockwave Medical, Inc | 1 | $113 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $110 |
| Bridgebio Pharma, Inc. | 5 | $90 |
| Scpharmaceuticals Inc. | 3 | $55 |
| Novo Nordisk | 2 | $35 |
| GSK | 2 | $31 |
| Baxter Healthcare | 1 | $26 |
| TG Therapeutics, Inc. | 1 | $26 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Bayer | 1 | $21 |
| Mannkind Corporation | 1 | $19 |
| Chiesi USA, Inc. | 1 | $18 |
| Merck | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rapiblyk$3,935
- Impella$537
- RESOLUTE ONYX$221
- LEQVIO$139
- ENSITE$133
- AVYCAZ$125
- CAMZYOS$125
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$113
- INVEGA SUSTENNA$101
- Tremfya$100
How this compares
$5,849 in reported general payments places this provider in the 75th percentile of 2,302 cardiovascular disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 12 | $116 |
| Lisinopril | 11 | $73 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Albany
- Augustin DelagoAlbany$1.8M
- Rizwan AlimohammadAlbany$349K
- Edward PhilbinAlbany$226K
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.